[ Inside the business ]

BIIB stock analysis

BIIB · Biogen Inc.

Biological products, (no diagnostic substances). Growing 11%.

Nothing unusual in its latest filings.

The future, in 7 questions

Priced in: 1.4× sales in 5 yrs. Evidence: sales +11% · 26¢ profit/$1.

01 What's priced in?1.4× sales in 5 yrs
Sales now$11.0B
Needed in 5 yrs$14.9B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales +11%, speeding up
No customer over 10%
Prepaid $56MSales +11%, speeding up
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 26¢ per $1, falling
'17'18'19'2026¢
Before running costs: 78% → 76%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares +0.5%/yrDebt $7.3B
07 What could break it?Nothing flagged

✓ All clear

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth +2%, +3%, then +11% vs. a year ago.

What could go wrong

Steadier than most.

It has moved 0.3× the market. In the 2008 crisis it fell 38% while the market fell 51%. Debt is moderate.

Speculative check

Not classified.

Not Self-funding because of: loss in the latest quarter, debt over 4× operating profit.

What they sell

24% Rare Disease Product Revenue.

Rare Disease Product Revenue 24% · Royalty Attributed To OCREVUS 13% · Fumarate 10% · Specialized Immunology 9% · other (latest quarter)

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Growth.

It earns cash, invests heavily, and still raises money to grow.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 647¢ of each $1 of profit.

Competitive advantage

6 of 6 years.

Returns beat its 6.3% cost of capital in 6 of the last 6 years. Gross margin went from 87% to 76%.

Future bets

21% on research.

$2.2B a year on R&D. $176M on equipment and buildings.

All figures from Biogen Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.